Keyword: Neon Therapeutics
There’s been a deal at the J.P. Morgan Healthcare Conference, but probably not with the largest names and certainly not big bucks.
Studies in mice suggest cancer vaccines made of frameshift peptides could stop or prevent tumor growth.
Moderna has pushed another four programs into phase 1 and started a phase 2 study of its Merck-partnered personalized cancer vaccine for patients with melanoma.
After four years at Neon and a career that’s shown him the many faces of biopharma, Robert Ang is ready to take the plunge and run his own company.
Neon's personalized neoantigen vaccine coupled with Opdivo staved off cancer longer than Opdivo alone in patients with lung, bladder and skin cancer.
Neon Therapeutics plans to use its IPO cash to push its lead candidate, a personalized neoantigen cancer vaccine, through phase 1.
Jan Lundberg, Ph.D., will retire next May as Dan Skovronsky, M.D., Ph.D., will be promoted to replace him.
Neon has signed a new R&D pact with gene-editing biotech CRISPR Therapeutics.
Efforts to develop effective, personalized cancer vaccines have been largely unsuccessful to date, but studies suggest the tide could be turning.
BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.